ArticleBMJ open2026

Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol.

Benjamin A Fisher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.